Inventiva SA (XPAR:IVA) Share Price

Company Profile

Business description
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Contact
50 rue de Dijon
Daix21121
FRA
T: +33 380447500
E: [email protected]
https://www.inventivapharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
84

Recommended

Higher sales and a new loan facility increase our conviction.

Shane Ponraj, CFA | 15 January 2026

We’ve raised our fair value estimate of Taiwan Semiconductor stock.

Phelix Lee | 15 January 2026

Watching sales growth and the potential for a major acquisition, here’s what we think of Netflix stock.

Matthew Dolgin, CFA | 15 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,226.70	45.90	0.50%
CAC 40	8,258.94	54.18	-0.65%
DAX 40	25,297.13	55.26	-0.22%
Dow JONES (US)	49,359.33	83.11	-0.17%
FTSE 100	10,235.29	3.65	-0.04%
HKSE	26,844.96	78.66	-0.29%
NASDAQ	23,515.39	14.63	-0.06%
Nikkei 225	53,936.17	174.33	-0.32%
NZX 50 Index	13,718.10	58.31	0.43%
S&P 500	6,940.01	4.46	-0.06%
S&P/ASX 200	8,903.90	48.10	0.54%
SSE Composite Index	4,101.91	10.69	-0.26%